PLLP inhibits the progression of WT p53 gastric cancer by reducing p53 protein ubiquitination by binding to TRIM59
Journal of Biological Chemistry · 2026-04 · 302 (4) · 111341
DOI: 10.1016/j.jbc.2026.111341 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2026-04. Verfasst von Zhenhao Quan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China; Department of Gastrointestinal Surgery, Affiliate…. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Stomach Neoplasms, Tripartite Motif Proteins, Intracellular Signaling Peptides and Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Gastric cancer (GC) is among the most common malignant tumors worldwide. The inhibition of p53 ubiquitination can inhibit the progression of GC. The mechanism through which plasmolipin (PLLP) regulates p53 ubiquitination in GC remains unclear. In this study, the correlation between PLLP expression and the prognosis of GC was analyzed on the basis of data from The Cancer Genome Atlas database, and the expression characteristics of PLLP and p53 were verified by immunohistochemistry. A PLLP overexpression/knockdown GC cell model was constructed, and cell proliferation, apoptosis, and invasion were detected by Cell Counting Kit-8, flow cytometry, and Transwell assays. Coimmunoprecipitation and Western blotting were used to analyze the PLLP-tripartite motif-containing 59 (TRIM59)-p53 regulatory axis. The antitumor effect of PLLP in vivo was verified by tumor formation experiments in nude mice. Cycloheximide tracking assays, coimmunoprecipitation, and ubiquitination analysis were used to determine the effect of PLLP on p53 stability. Combined with bioinformatics prediction and experimental verification, the interaction between PLLP and the E3 ubiquitin ligase TRIM59 and its regulatory effect on the ubiquitination and degradation of p53 were analyzed. Flow cytometry and Transwell assays were used to verify the biological effect of the PLLP-TRIM59-p53 axis. We found that PLLP was downregulated in GC (p < 0.05). PLLP interacts with TRIM59, inhibits TRIM59-mediated ubiquitination degradation of p53, and inhibits the progression of GC cells with WT p53. PLLP may be used as a potential biomarker for targeted therapy of GC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China; Department of Gastrointestinal Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
- Department of Gastrointestinal Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
- Department of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China. Electronic address: qwwer12@126.com.
Zitieren
APA
Quan, Z., Lin, L., Xu, F., Zhou, C., Huang, R., Sun, K., & Jiang, H. (2026). PLLP inhibits the progression of WT p53 gastric cancer by reducing p53 protein ubiquitination by binding to TRIM59. Journal of Biological Chemistry, 302(4), 111341. https://doi.org/10.1016/j.jbc.2026.111341
Vancouver
Quan Z, Lin L, Xu F, Zhou C, Huang R, Sun K, et al. PLLP inhibits the progression of WT p53 gastric cancer by reducing p53 protein ubiquitination by binding to TRIM59. Journal of Biological Chemistry. 2026;302(4):111341. doi:10.1016/j.jbc.2026.111341
BibTeX
@article{Quan2026,
author = {Quan, Zhenhao and Lin, Lin and Xu, Feipeng and Zhou, Caijin and Huang, Renwei and Sun, Kaiyu and Jiang, Haiping},
title = {PLLP inhibits the progression of WT p53 gastric cancer by reducing p53 protein ubiquitination by binding to TRIM59},
journal = {Journal of Biological Chemistry},
year = {2026},
volume = {302},
number = {4},
pages = {111341},
doi = {10.1016/j.jbc.2026.111341}
}
EUVIMED